Incyte lifts annual sales forecast for blood cancer drug after solid quarter

Incyte Corp. exceeded Q2 Wall Street estimates, prompting an upward revision to its 2025 Jakafi sales forecast to $3.0-$3.05 billion, as strong demand drove Jakafi sales up 8% to $763.8 million and Opzelura sales up 35% to $164.5 million, contributing to a 3.5% premarket share rise. The company's outlook is further strengthened by a recent royalty settlement with Novartis, easing future Jakafi costs, while new FDA approvals for Zynyz and Monjuvi, alongside Opzelura's growth, position Incyte for sustained performance as Jakafi approaches its 2028 patent expiration.

Analysis

Incyte Corp. demonstrated robust operational performance in its second quarter, exceeding Wall Street estimates on both revenue and earnings. Total revenue reached $1.22 billion against a forecast of $1.15 billion, with adjusted EPS of $1.57 beating the $1.47 consensus. This outperformance was driven by stronger-than-expected sales from its flagship blood cancer drug, Jakafi, which grew 8% year-over-year to $763.8 million, and its growth-driver, Opzelura, which saw sales jump 35% to $164.5 million. Consequently, management raised its full-year 2025 sales forecast for Jakafi to a range of $3.0 billion to $3.05 billion, positioning the midpoint slightly above the analyst average of $3.01 billion. The company's financial outlook is further enhanced by the recent settlement with Novartis, which, despite a one-time $280 million payment, secures a 50% reduction in future royalty rates on Jakafi sales from January 2025, promising significant cost relief. This, combined with the strong uptake of Opzelura and recent FDA approvals for Zynyz and Monjuvi, signals a proactive strategy to mitigate the impact of Jakafi's potential patent expiration in 2028, a thesis validated by the 3.5% premarket stock increase.

Key Decisions for Investors

• Investors should view the beat-and-raise quarter as a confirmation of solid execution, with the revised Jakafi guidance and strong Opzelura growth providing improved visibility into near-term performance.
• The settlement with Novartis materially de-risks Jakafi's future profitability by significantly lowering its royalty burden from 2025, strengthening the drug's cash flow contribution ahead of its 2028 patent cliff.
• Monitor the continued sales trajectory of Opzelura and initial contributions from new approvals like Zynyz, as these are critical indicators of the company's success in diversifying its revenue base and mitigating long-term patent risk.